An observational study in Myocardial Infarction, Myocardial Ischemia and STEMI, sponsored by Luzerner Kantonsspital. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by Luzerner Kantonsspital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.
Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 6th largest by planned enrollment of the 18 observational ones that give a count, is one of 10 that started in 2021, is one of 18 observational ones, reaches primary completion later than 4 of the 19 other live ones, and was the 53rd registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:
École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · Sites in Switzerland
Ages 18+ · Healthy volunteers
Fondazione Don Carlo Gnocchi ETS · Sites in Switzerland, Belgium, Italy and 1 more country
Ages 18+
Novo Nordisk A/S · Sites in Switzerland, Austria, Denmark and 3 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 334 across the 51 interventional studies, 1,526 across the 18 observational. Of the 44 that completed or were terminated, 9 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
Luzerner Kantonsspital is the lead sponsor of 61 studies on the registry; 22 are open to participants now.
Luzerner Kantonsspital has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
7 of the studies in Myocardial Infarction with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07810686École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital CareSmartphone AI Assistance for Prehospital ECG Interpretation | 2026-11-30 |
| NCT05859620University Hospital, Basel, SwitzerlandImplementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery | 2026-12 |
| NCT04988672Luzerner KantonsspitalOPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction | 2026-12-31 |
| NCT07252856Fondazione Don Carlo Gnocchi ETSTranscultural Digital Solutions in Phase III Cardiac Rehabilitation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Myocardial Infarction with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the OPTIMISER Registry is to prospectively and retrospectively collect baseline, clinical and procedural data in patients who present with AMI and are treated with PCI as well as prospectively collect the clinical outcome data. Outcomes will be compared in different clinical subgroups. The impact of PCI in AMI in general as well as cardiovascular outcomes after AMI will be assessed.
To assess procedural success and clinical outcomes among persons with AMI, who undergo PCI and/ or CABG for AMI (STEMI or NSTEMI)
In an all-comers design, virtually any AMI patient treated with PCI or CABG at the Cardiology Division of Lucerne Cantonal Hospital and giving consent may be included. We expect a total inclusion rate of around 400 patients per year at the LUKS. The prospective recruitment is planned to continue for 10 years, which results in 4000 patients in the prospective arm. In addition, a retrospective arm will include a random sample of 500 patients who presented with AMI and were treated with PCI or CABG in the 5 years prior to study start (2016-2020).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rate of major adverse cardiac and cerebrovascular events (MACCE) (including new AMI, stroke or cardiovascular death) at 1 year
Time frame: at 1 year
Rate of major adverse cardiac and cerebrovascular events (MACCE)
Time frame: 1, 2, 5 and 10 years
Rate of new AMI
Time frame: 1, 2, 5 and 10 years
Rate of TIA or stroke
Time frame: 1, 2, 5 and 10 years
Rate of stent thrombosis
Time frame: 1, 2, 5 and 10 years
Rate of target vessel revascularization
Time frame: 1, 2, 5 and 10 years
Rate of target lesion failure
Time frame: 1, 2, 5 and 10 years
Rate of ischemia-driven revascularization
Time frame: 1, 2, 5 and 10 years
Rate of unstable angina
Time frame: 1, 2, 5 and 10 years
Rate of rehospitalization for recurrent angina
Time frame: 1, 2, 5 and 10 years
Rate of hospitalization for heart failure
Time frame: 1, 2, 5 and 10 years
Rate of rehospitalisation for heart failure, resuscitated cardiac arrest or implantable cardioverter-defibrillator (ICD) implantation at follow- up.
Time frame: 1, 2, 5 and 10 years
Rate of cardiovascular mortality
Time frame: 1, 2, 5 and 10 years
Rate of all-cause mortality
Time frame: 1, 2, 5 and 10 years
Rate of bleeding events (access site or non-access site related) according to the BARC classification.
Time frame: 1, 2, 5 and 10 years
Rate of vascular complications (according to VARC criteria)
Time frame: 1, 2, 5 and 10 years
Rate of new York Heart Association (NYHA) class
Time frame: 1, 2, 5 and 10 years
Rate of cardiogenic shock
Time frame: 1, 2, 5 and 10 years
Rate of acute renal failure
Time frame: 1, 2, 5 and 10 years
Rate of new atrial fibrillation
Time frame: 1, 2, 5 and 10 years
Rate of new ventricular arrhythmias
Time frame: 1, 2, 5 and 10 years
Rate of major adverse limb events (MALE)
Time frame: 1, 2, 5 and 10 years
Rate of periprocedural complications (e.g. coronary perforations, no- reflow)
Time frame: 1, 2, 5 and 10 years
Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.
Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 71 months is above that.
Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Luzerner Kantonsspital